Table II.
Outcome measures at 12-month follow-up
| Cohort |
Intermediate and high-risk PE |
|||||
|---|---|---|---|---|---|---|
| AC (n = 275) | Reperfusion (n = 107) | P value | AC (n = 169) | Reperfusion (n = 107) | P value | |
| VOI at PE diagnosis | 28% | 47% | < .001 | 31% | 47% | < .001 |
| RPVO | 25 (9) | 23 (21) | .001 | 14 (8) | 23 (22) | < .001 |
| Changes in RV function | .021 | .043 | ||||
| Persistent RV dysfunction | 28/79 (35) | 12/66 (18) | 21/62 (34) | 12/66 (18) | ||
| Improvement in RV function | 51/79 (65) | 54/66 (82) | 41/62 (66) | 54/66 (82) | ||
| New RV dysfunction | 13/73 (18) | 3/14 (21) | .749 | 6/35 (17) | 3/14 (21) | .726 |
| PE recurrence | 17 (6) | 8 (8) | .646 | 11 (7) | 8 (8) | .757 |
| CTEPH | 13 (5) | 9 (8) | .488 | 11 (7) | 9 (8) | .721 |
| Readmissions | 127 (46) | 35 (33) | .031 | 80 (47) | 35 (33) | .043 |
| PE-related | 34 (12) | 13 (12) | 23 (14) | 13 (12) | ||
| PE non-related | 93 (34) | 22 (21) | 57 (34) | 22 (21) | ||
| In-hospital mortality | 41/325 (13) | 21/128 (16) | .291 | 30/208 (14) | 21/128 (16) | .623 |
| Mortality (discharge to 1 year) | 21/284 (7) | 2/107 (2) | .038 | 15/178 (8) | 2/107 (2) | .024 |
| Cancer | 11/21 (52) | 0 | 9/15 (60) | 0 | ||
| Respiratory failure | 2/21 (10) | 1/2 (50) | 1/15 (7) | 1/2 (50) | ||
| COVID | 2/21 (10) | 0 | 0 | 0 | ||
| Septic shock | 1/21 (4) | 1/2 (50) | 1/15 (7) | 1/2 (50) | ||
| Stroke | 2/21 (10) | 0 | 2/15 (13) | 0 | ||
| Unknown | 3/21 (14) | 0 | 2/15 (13) | 0 | ||
| Total mortality | 62/325 (19) | 23/128 (23) | .786 | 45/208 (22) | 23/128 (18) | .417 |
AC, Anticoagulation; CTEPH, chronic thromboembolic pulmonary hypertension; PE, pulmonary embolism; RPVO, residual pulmonary vascular obstruction; RV, right ventricular; VOI, vascular obstructive index.
Data are presented as number/total (%).